These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36781382)

  • 1. Preparation, characterization, and pharmacokinetics of oridonin-loaded liposomes.
    Lin FE; Zhang XY; Zhang YP; Wang J
    Biomed Chromatogr; 2023 May; 37(5):e5603. PubMed ID: 36781382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preparation of freeze-dried long-circulation oridonin liposomes and their pharmacokinetics in rats].
    Lin H; Qu C; Yu Y; Tang Y; Sun X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 42(6):638-43. PubMed ID: 24421229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation, Characterization, and Evaluation of Liposomes Containing Oridonin from
    Wang Y; Wang M; Lin F; Zhang X; Zhao Y; Guo C; Wang J
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of the process variables of tilianin-loaded composite phospholipid liposomes based on response surface-central composite design and pharmacokinetic study.
    Zeng C; Jiang W; Tan M; Yang X; He C; Huang W; Xing J
    Eur J Pharm Sci; 2016 Mar; 85():123-31. PubMed ID: 26883760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma.
    Xu W; Sun J; Zhang TT; Ma B; Cui SM; Chen DW; He ZG
    Acta Pharmacol Sin; 2006 Dec; 27(12):1642-6. PubMed ID: 17112421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of verapamil on the pharmacokinetics of oridonin in rats.
    Liu J; Zhang N; Li N; Fan X; Li Y
    Pharm Biol; 2019 Dec; 57(1):787-791. PubMed ID: 31747844
    [No Abstract]   [Full Text] [Related]  

  • 7. Preparation, Characterization and in vivo Study of Borneol-Baicalin-Liposomes for Treatment of Cerebral Ischemia-Reperfusion Injury.
    Zhang Y; Liu S; Wan J; Yang Q; Xiang Y; Ni L; Long Y; Cui M; Ci Z; Tang D; Li N
    Int J Nanomedicine; 2020; 15():5977-5989. PubMed ID: 32904394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of stealth liposomes on pharmacokinetics, tissue distribution and anti-tumor activity of oridonin.
    Wang C; Wei Y; Yu L; Zhang L
    PDA J Pharm Sci Technol; 2009; 63(5):409-16. PubMed ID: 20158047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation, characterization, and anti-colon cancer activity of oridonin-loaded long-circulating liposomes.
    Gao C; Zhang L; Tang Z; Fang Z; Ye X; Yu W
    Pharm Dev Technol; 2021 Dec; 26(10):1073-1078. PubMed ID: 34543167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin.
    Zhang P; Liu Y; Feng N; Xu J
    Int J Pharm; 2008 May; 355(1-2):269-76. PubMed ID: 18242895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of nano liposomes of Orthosiphon stamineus ethanolic extract in soybean phospholipids.
    Aisha AF; Majid AM; Ismail Z
    BMC Biotechnol; 2014 Mar; 14():23. PubMed ID: 24674107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers.
    Jia L; Shen J; Zhang D; Duan C; Liu G; Zheng D; Tian X; Liu Y; Zhang Q
    Int J Biol Macromol; 2012 Apr; 50(3):523-9. PubMed ID: 22301003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes].
    Deng X; He D; Xiong HR; Zhou YL; Zhang JQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 46(5):688-91. PubMed ID: 26619536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of oridonin in rat plasma by reverse-phase high-performance liquid chromatography.
    Ge J; You-Wei W; Xiao-Cong L; Ji-Yue C
    J Pharm Biomed Anal; 2007 Jan; 43(2):793-7. PubMed ID: 17011736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation, Characterization, and In Vitro Pharmacodynamics and Pharmacokinetics Evaluation of PEGylated Urolithin A Liposomes.
    Yi S; Zhang C; Hu J; Meng Y; Chen L; Yu H; Li S; Wang G; Zheng G; Qiu Z
    AAPS PharmSciTech; 2021 Jan; 22(1):26. PubMed ID: 33404864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
    Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
    Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The tissue distribution in mice and pharmacokinetics in rabbits of oridonin-solid lipid nanoparticles].
    Zhang DR; Ren TC; Lou HX; Xing J
    Yao Xue Xue Bao; 2005 Jun; 40(6):573-6. PubMed ID: 16144328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin.
    Zheng D; Duan C; Zhang D; Jia L; Liu G; Liu Y; Wang F; Li C; Guo H; Zhang Q
    Int J Pharm; 2012 Oct; 436(1-2):379-86. PubMed ID: 22732673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7-Ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: optimized formulation, characterization and in-vivo evaluation.
    Wang S; Ye T; Yang B; Yi X; Yao H
    Drug Dev Ind Pharm; 2013 Feb; 39(2):393-401. PubMed ID: 22583043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and characterization of liposomes encapsulating chitosan nanoparticles.
    Huang YZ; Gao JQ; Liang WQ; Nakagawa S
    Biol Pharm Bull; 2005 Feb; 28(2):387-90. PubMed ID: 15684508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.